Nuvectis Pharma Inc

NASDAQ:NVCT   12:59:58 AM EDT
7.27
+0.07 (+0.97%)
Earnings Announcements

Nuvectis Pharma Reports Third Quarter Results

Published: 11/08/2022 15:47 GMT
Nuvectis Pharma Inc (NVCT) - Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights.
Nuvectis Pharma - Dose Escalation Portion of Phase 1 Clinical Trial of Nxp800 is Ongoing, Phase 1b Dose Expansion Portion Expected to Begin in Q1 2023.
Nuvectis Pharma - Investigational New Drug Application-enabling Studies for Nxp900 Are Ongoing, Submission of Ind Or Equivalent Expected in Q1 2023.
Nuvectis Pharma Inc - Continue to Operate Efficiently With an Expected Cash Runway Into Second Half of 2024.
Nuvectis Pharma Inc - Qtrly Loss per Share $0.42.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.39

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.43

More details on our Analysts Page.